Short description
Primmune Therapeutics is a Biotechnology company.
Description
Primmune Therapeutics is developing small molecule, orally-administered toll-like receptor 7 (TLR7) agonists to attack tumors and potentiate adaptive cancer immunotherapies, such as checkpoint inhibitors, to improve overall response rates and treatment durability.
Last funding
No Way
Sign in for full access
Total funding
$$3123123
Sign in for full access
Location
San Diego, California, United States, North America
Founded on
January 1, 2017
Non-profit?
No
Acquired?
No
Employees count
1-10
Revenue range
$34056 - 789030
Sign in for full access
Investors
Cannot Access, Cannot Access, Absolutely Noaccess, Noaccessforu, Cannot Access, Blurry Noaccess, Absolutely Noaccess, Noaccess
Sign in for full access
Founders
James Appleman, Paulo Rangel